Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/NMPA/Paliperidone Extended-Release Tablets

Approved

化学药品

Paliperidone Extended-Release Tablets

Janssen-Cilag International NV🇨🇳 National Medical Products Administration

Approval Date: Oct 10, 2021
Approval ID: 8DqlgnLjF1N
Company: Janssen-Cilag International NV
Type: 化学药品

Approval Details

Approval Id: 8DqlgnLjF1N
Approval Number: 国药准字HJ20160552
Generic Name: 帕利哌酮缓释片
Generic Name En: Paliperidone Extended-Release Tablets
Trade Name: 芮达
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 3mg
Reg Date: 2021-10-10
Expired Date: 2026-10-09
Company Name: Janssen-Cilag International NV
Company Detail Path: /organization/janssen-cilag-international-nv

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Oct 10, 2021

Approval ID

8DqlgnLjF1N

Type

化学药品

Back to NMPA Approvals

芮达 - NMPA Drug Approval Details